Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Liabilities and Shareholders Equity: 2022-2023

Historic Liabilities and Shareholders Equity for Therapeutics (LENZ) over the last 2 years, with Sep 2023 value amounting to $266.2 million.

  • Therapeutics' Liabilities and Shareholders Equity fell 20.49% to $266.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was $1.2 billion, marking a year-over-year change of. This contributed to the annual value of $321.9 million for FY2022, which is N/A change from last year.
  • Per Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $266.2 million for Q3 2023, which was down 7.25% from $287.0 million recorded in Q2 2023.
  • Over the past 5 years, Therapeutics' Liabilities and Shareholders Equity peaked at $378.6 million during Q1 2022, and registered a low of $266.2 million during Q3 2023.
  • In the last 2 years, Therapeutics' Liabilities and Shareholders Equity had a median value of $321.9 million in 2022 and averaged $321.8 million.
  • Data for Therapeutics' Liabilities and Shareholders Equity shows a maximum YoY fell of 20.49% (in 2023) over the last 5 years.
  • Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $321.9 million in 2022, then fell by 20.49% to $266.2 million in 2023.
  • Its Liabilities and Shareholders Equity was $266.2 million in Q3 2023, compared to $287.0 million in Q2 2023 and $310.0 million in Q1 2023.